Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10158412 | Clinical Therapeutics | 2018 | 10 Pages |
Abstract
Concurrent administration of imrecoxib and fluconazole did not seem to change imrecoxib's safety profile. The ratio (imrecoxibâ¯+â¯fluconazole/imrecoxib) for AUC0-t was 1.72 (90% CI, 1.41-2.11) and for Cmax it was 1.88 (90% CI, 1.59-2.21). Hence, it is necessary to adjust the imrecoxib dose when it is concurrently used with other CYP2C9 inhibitors.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Cheng-zi MS, Yi BS, Xiang-yu PhD, Yi-fan PhD, Wen-xing PhD, Rong-hua PhD, Da-fang PhD, Xiao-yan PhD,